Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Interim Management Statement

10 May 2010 07:00

RNS Number : 5791L
Tarsus Group PLC
10 May 2010
 



 

 

 

TARSUS GROUP plc

 

Interim Management Statement

 

Tarsus Group Plc ("Tarsus" or "the Group"), the international business-to-business media group, is today publishing its Interim Management Statement relating to the period from the publication of its Preliminary Results on 8 March 2010 to 9 May 2010.

 

Trading Performance

 

Trading for the period has been in line with the Board's expectations. A summary of major developments includes:

 

§ US - continued recovery & momentum

 

The Medical division continues to gain momentum. The April Orlando event produced revenues well ahead of last year, driven by very strong growth from its education programmes. Exhibition and conference revenues also grew for the first time in 18 months.

 

§ France - management action retains margins within expectations

 

A number of small exhibitions have taken place in France since 8 March. As expected, the declining revenue trends experienced in the second half of 2009 have continued into the first half of 2010. Strong cost management has resulted in margins remaining within our expectations.

 

§ Emerging Markets

 

No material events have taken place since 8 March.

 

Financial Position

 

There have been no significant changes to the financial position of the Group since the publication of the Preliminary Results on 8 March 2010.

 

Outlook

 

At our preliminary results at the start of March we announced the launch of "Project 50/13" to accelerate our scale in Emerging Markets. Our business infrastructure in the region is now established and Tarsus has a much improved platform within Asia and the Middle East from which to continue to drive strong growth.

 

As in previous years, the Group's revenues remain heavily second-half weighted and, overall, forward bookings remain at a similar level to 2009.

 

The French portfolio is weighted towards the 4th quarter of the year and we are now seeing signs of stabilisation in that market, with forward bookings for 4th quarter events at similar levels to last year. Given the current economic outlook for Europe, we continue to remain cautious.

 

US sales are strong and ahead of 2009, driven mainly by our Off-Price (discount clothing) and Medical divisions. Labelexpo America's sales are marginally behind the previous edition, owing to smaller exhibitors booking later in the cycle.

 

In the Emerging Markets division, the Group's largest event this year is MEBA (business aviation) which takes place in Dubai for which forward bookings are well ahead of the previous cycle.

 

Our view of trading for 2010 is unchanged with long term exhibition trends intact. The recovery in the US economy is benefiting our business in that market and we are seeing good growth prospects and opportunities in Emerging Markets. Our strong brands, diversified portfolio of market leading events and increased focus on Emerging Markets leave Tarsus well positioned for the future.

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Ashley Milton, Group Finance Director 020 8846 2700

 

Media:

 

Madano Partnership

Matthew Moth 020 7593 4000

 

Investors/Analysts:

 

IRfocus

Neville Harris 020 7593 4015

 

Scott Harris

Stephen Scott, Jeremy Wiseman 020 7653 0030

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSKKODKABKDOPK
Date   Source Headline
12th Jan 20187:00 amRNSTrading Update & launch of next phase of strategy
29th Dec 201710:03 amRNSTotal Voting Rights
13th Dec 20173:22 pmRNSScrip Dividend Circular (the "Circular")
5th Dec 201711:45 amRNSHolding(s) in Company
30th Nov 201710:33 amRNSTotal Voting Rights and Capital
21st Nov 20177:00 amRNSCapital Markets Seminar and Trading Update
14th Nov 20177:00 amRNSSite visit to Dubai Airshow
9th Nov 201710:41 amRNSBlock Listing Six Monthly Return
2nd Nov 20177:00 amRNSChange of Advisers
12th Oct 20177:00 amRNSTrading Statement
26th Sep 20177:00 amRNSAnalyst and Investor Site Visit
22nd Sep 20173:55 pmRNSHolding(s) in Company
12th Sep 20177:00 amRNSExpansion of Mexican Joint Venture
6th Sep 201711:38 amRNSBlock Listing Six Monthly Return
31st Aug 20179:31 amRNSTotal Voting Rights
29th Aug 20173:31 pmRNSDirector/PDMR Shareholding
16th Aug 20174:07 pmRNSHalf-year Report
2nd Aug 20171:38 pmRNSDirector/PDMR Shareholding
31st Jul 20172:42 pmRNSTotal Voting Rights
27th Jul 20175:05 pmRNSDirector/PDMR Shareholding
26th Jul 20177:00 amRNSHalf-year Report
11th Jul 201712:42 pmRNSApplication for Admission
30th Jun 20174:09 pmRNSTotal Voting Rights
21st Jun 201712:13 pmRNSResult of AGM
5th Jun 201711:24 amRNSScrip Dividend Circular
31st May 201710:09 amRNSTotal Voting Rights
19th May 20171:42 pmRNSNotice of AGM
18th May 201712:05 pmRNSHolding(s) in Company
17th May 20177:00 amRNSTrading Update
9th May 20172:45 pmRNSBlock Listing Six Monthly Return
28th Apr 201711:05 amRNSTotal Voting Rights
4th Apr 20175:17 pmRNSHolding(s) in Company
4th Apr 20175:16 pmRNSDirector/PDMR Shareholding
31st Mar 201710:37 amRNSTotal Voting Rights
30th Mar 20176:10 pmRNSDirector/PDMR Shareholding
17th Mar 20172:01 pmRNS2016 Annual Report
16th Mar 20172:29 pmRNSDirector/PDMR Shareholding
15th Mar 20178:41 amRNSHolding(s) in Company
6th Mar 20175:45 pmRNSDirector/PDMR Shareholding
6th Mar 20175:44 pmRNSDirector/PDMR Shareholding
1st Mar 20174:04 pmRNSApplication for Block Listing
1st Mar 20177:00 amRNSFinal Results
8th Feb 201712:19 pmRNSDirector Declaration
1st Feb 201712:02 pmRNSTotal Voting Rights
25th Jan 20177:00 amRNSCompletion of acquisition
17th Jan 201711:14 amRNSApplication for Admission
10th Jan 20177:00 amRNSYear-end Trading Update
30th Dec 20169:03 amRNSTotal Voting Rights
22nd Dec 20167:12 amRNSAcquisition of Hometex
14th Dec 20163:26 pmRNSScript Dividend Circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.